C
Christoph Kleinschnitz
Researcher at University of Duisburg-Essen
Publications - 497
Citations - 16983
Christoph Kleinschnitz is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Stroke. The author has an hindex of 60, co-authored 419 publications receiving 13199 citations. Previous affiliations of Christoph Kleinschnitz include University of Hamburg & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
Sven Jarius,Klemens Ruprecht,Brigitte Wildemann,Tania Kuempfel,Marius Ringelstein,Christian Geis,Ingo Kleiter,Ingo Kleiter,Christoph Kleinschnitz,Achim Berthele,Johannes Brettschneider,Kerstin Hellwig,Bernhard Hemmer,Ralf A. Linker,Ralf A. Linker,Florian Lauda,Christoph Mayer,Hayrettin Tumani,Arthur Melms,Corinna Trebst,Martin Stangel,Martin Marziniak,Frank Hoffmann,Sven Schippling,Jürgen H. Faiss,Oliver Neuhaus,Barbara Ettrich,Christian Zentner,Kersten Guthke,Ulrich Hofstadt-van Oy,Reinhard Reuss,Hannah L. Pellkofer,Ulf Ziemann,Peter Kern,Klaus Peter Wandinger,Florian Then Bergh,Tobias Boettcher,Stefan Langel,Martin Liebetrau,Paulus S. Rommer,Sabine Niehaus,Christoph Münch,Alexander Winkelmann,Uwe K Zettl U,Imke Metz,Christian Veauthier,Jörn P Sieb,C. Wilke,Hans Hartung,Orhan Aktas,Friedemann Paul +50 more
TL;DR: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
Journal ArticleDOI
Animal models of ischemic stroke and their application in clinical research.
TL;DR: These models differ from human stroke, which particularly affects elderly people who have various cerebrovascular risk factors and optimizing the study design of preclinical trials might increase the translational potential of animal stroke models.
Journal ArticleDOI
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis
Christoph Kleinschnitz,Guido Stoll,Martin Bendszus,Kai Schuh,H. U. Pauer,Peter Burfeind,Christoph Renné,David Gailani,Bernhard Nieswandt,Thomas Renné +9 more
TL;DR: As FXII appears to be instrumental in pathologic fibrin formation but dispensable for hemostasis, FXII inhibition may offer a selective and safe strategy for preventing stroke and other thromboembolic diseases.
Journal ArticleDOI
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration.
Christoph Kleinschnitz,Henrike Grund,Kirstin Wingler,Melanie E. Armitage,Emma S Jones,Manish Mittal,David Barit,Tobias Schwarz,Christian Geis,Peter Kraft,K. Barthel,Michael K. Schuhmann,Alexander M. Herrmann,Sven G. Meuth,Guido Stoll,Sabine Meurer,Anja Schrewe,Lore Becker,Valerie Gailus-Durner,Helmut Fuchs,Thomas Klopstock,Martin Hrabé de Angelis,Karin Jandeleit-Dahm,Ajay M. Shah,Norbert Weissmann,Harald H.H.W. Schmidt +25 more
TL;DR: The identification of NOx4 as a major source of oxidative stress in stroke and demonstration of dramatic protection after stroke in mice by NOX4 deletion or NOX inhibition, opens up new avenues for treatment.
Journal ArticleDOI
Targeting Platelets in Acute Experimental Stroke Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding
Christoph Kleinschnitz,Miroslava Pozgajova,Mirko Pham,Martin Bendszus,Bernhard Nieswandt,Guido Stoll +5 more
TL;DR: Inhibition of early steps of platelet adhesion to the ischemic endothelium and the subendothelial matrix may offer a novel and safe treatment strategy in acute stroke.